Drugs / 99mTc-ABH2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03546478 | Jun 2015 → May 2017 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06194565 | Mar → Dec 2023 | breast cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-ABH2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06194565 ↗ |
| Modality | Diagnostic / imaging agent | “This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the diagnostic performance and evaluation efficacy of 99mTc-ABH2 in...” NCT03546478 ↗ |
| Route | Intravenous | “A single dose of 370±54 Mega-Becquerel (MBq)99mTc-ABH2 will be injected intravenously.” NCT03546478 ↗ |